Kornimate/medical-research-clean huggingface dataset:
evaluation of the efficacy of a turmeric extract (arantal®) in patients with osteoarthritis of the knee (gonarthrosis).

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to determine the efficacy and the tolerance on 15 days of a turmeric extract (arantal®) on pain related to gonarthrosis.


Eligibility criteria:
inclusion criteria: * patient is 40 through 80 years of age * subject diagnosed with femorotibial osteoarthritis of the knee (diagnosed according to the clinical and radiologic criteria of acr), * patient's assessment of arthritis pain measurement on the last 24 hours of at least 50 mm on vas, * patient has not received any nsaids within 72 hours and any analgesics within 24 hours, * patients with chronic knee pain (i.e., knee pain at least every other day during the month preceding inclusion), * patients with radiologic knee osteoarthritis (kellgren-lawrence grade 2-4, on radiography less than 12 months old), * patients having signed the informed consent, * patients capable of comprehend the study instructions. exclusion criteria: * related to the osteoarthritis pathology: * osteoarthritis linked to a metabolic arthropathy: chondrocalcinosis already diagnosed or defined by calcium edging on at least one femorotibial joint space, gout..., * predominant associated symptomatic femoropatellar osteoarthritis, * chondromatosis or villonodular synovitis of the knee, * recent trauma (\< 1 month) of the knee responsible for the pain, * knee joint effusion justifying an evacuation through puncturing, * inflammatory flare (night pain, joint effusion) corresponding to a kofus score less than 7, * pathology potentially interfering with the evaluation (metabolic inflammatory arthropathy, rheumatoid arthritis, lower limb radiculalgia, arthritis...), * related to previous and associated treatments: * corticosteroids injection in the previous month, whatever the joint concerned, * hyaluronan injection in the evaluated knee during the previous 6 months, * patient who took nsaid in the 72 hours prior to inclusion or analgesics in the 24 hours prior to inclusion, * slow-acting drugs for oa and/or dietary supplements taken within less than 3 months prior to the study product administration or for which the dose has been modified in the last three months (ex: chondroitin sulfate, diacerein, soy and avocado unsaponifiables, oxaceprol, granions de cuivre, glucosamine, phytotherapy for oa, homeopathy for oa...), * anticoagulant treatment without gastric protection, * general corticotherapy, * contraindication to paracetamol. * related to associated pathologies: * patient suffering from serious associated illness (liver failure, kidney failure, non-controlled cardiovascular diseases...), * peptic ulcer. * related to patients: * pregnant or breastfeeding women * pre-menopausal women with no contraception * patients unable to write * patients enrolled in a clinical trial in the previous 3 months * patients under juristic protection or under guardianship.

Keywords: osteoarthritis, knee osteoarthritis joint diseases arthritis rheumatic diseases
endothelial function guided therapy in patients with non-obstructive coronary artery disease

Conditions: Non-obstructive Coronary Artery Disease

Summary: the purpose of this study is to systematically evaluate the clinical application value of vascular endothelial function examination in patients with non-obstructive coronary artery disease.

the study will be carried out in two stages. phase i is mainly intended to evaluate the effects of vascular eft on the prescription of doctors and the application rate of mid and long-term secondary prevention medication in patients. if the results are positive, the sample size and observation time will be further expanded in phase ii to evaluate its impact on the cardiovascular events of patients, as well as its cost-effectiveness.

Eligibility criteria:
inclusion criteria: * 1. age: 18 years or older; * 2. patients with nocad defined by ct or cag results of less than 50% occlusion; * 3. having signed their written informed consent. exclusion criteria: * 1. left ventricular ejection fraction ≤ 50%; * 2. serious endocrine diseases (severe hyperthyroidism, hypothyroidism); * 3. severe liver diseases (jaundice hepatitis, liver cirrhosis, liver failure); * 4. severe nephropathy (uremia, renal failure); * 5. severe inflammatory diseases (severe infection, lupus erythematosus, etc.); * 6. malignant tumor; * 7. mental disorders or cognitive disorders; * 8. participating in other interventional clinical trials; * 9. there are any other factors that the treating doctors think are not suitable for inclusion or completion of this study.

Keywords: non invasive endothelial function test non-obstructive coronary artery disease major adverse cardiovascular events
a study of anlotinib hydrochloride capsules in subjects with diffuse large b-cell lymphoma

Conditions: Diffuse Large B-cell Lymphoma

Summary: this is an open-label, single-center, single-arm study to evaluate the efficacy and safety of anlotinib hydrochloride capsules in subjects with diffuse large b-cell lymphoma.


Eligibility criteria:
inclusion criteria: * 1. ≥18 years old; eastern cooperative oncology group (ecog) performance status of 0 or 1, life expectancy≥ 12 weeks. 2. histopathologically confirmed diffuse large b-cell lymphoma (dlbcl) . 3. has received at least 2 lines of systemic treatment. 4. at least one measurable lesion in vertical directions(based on lugano 2014). 5.adequate organ system function. 6. male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ; no pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization. 7. understood and signed an informed consent form. exclusion criteria: * 1. dlbcl transformed from indolent lymphoma (such as fl), primary testicular dlbcl, primary central nervous system lymphoma, mixed lymphoma (such as b cell lymphoma that cannot be classified between hl and dlbcl) tumor, etc.), richter's transformed dlbcl. 2. has central nervous system (cns) invasion. 3. has received vascular endothelial growth inhibitor, such as sunitinib, sorafenib, pazopanib, imatinib, famitinib, apatinib, anlotinib and so on. 4. has other malignancies (except cured skin basal cell carcinoma and cervical carcinoma in situ) within 3 years. 5. has a history of immunodeficiency. 6. has multiple factors affecting oral medication. 7.has uncontrollable or important cardiovascular disease. 8.has any severe and/or uncontrolled diseases. 9. has received surgery, or unhealed wounds within 4 weeks before the first administration. 10. has received systemic steroid therapy within 7 days before the first administration. 11. imaging (ct or mri) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear. 12. has any bleeding symptoms or treated with anticoagulants or vitamin k antagonists. 13. has arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident including transient ischemic attack, deep vein thrombosis and pulmonary embolism. 14. has psychotropic substances abuse or a mental disorder. 15. has received autologous hematopoietic stem cell transplantation within 3 months before the first administration, or have received allogeneic hematopoietic stem cell transplantation, or have graft-versus-host reaction. 16. has received other anti-tumor therapy within 4 weeks before the first administration. 17.according to the judgement of the researchers, there are other factors that may lead to the termination of the study. 18. unsuitable for anlotinib hydrochloride.
patient education before orthognathic surgery

Conditions: Malocclusion; Anxiety; Micrognathism; Prognathism

Summary: to evaluate the effectiveness in the use of an educational material through: assessment of knowledge about post-operative orthognathic surgery; assessing levels of anxiety with the survey of anxiety inventory-state-trait; clinical evaluation of self-care in the management of postoperative signs and symptoms

it is a clinical randomized controlled trial being developed from february 2013 to september 2015, divided into two phases: a pilot study without randomization for impact testing and evaluation of intervention and, in the second time, the clinical randomized study with possible changes after the pilot study. will be entered in the study patients undergoing maxillofacial surgery originating at outpatient clinic located in the municipality of são paulo. the study aims to evaluate the effects of educational material in postoperative education orthognathic surgery, with intervals between pre and postoperative serials. recruitment plan of patients: the patients seen in oral and maxillofacial surgery and traumatology clinic located in the municipality of são paulo with indication for orthognathic surgery will be covered by personally and invited to participate in intervention research. to control the bias will be included in the study patients of the same surgical team, to ensure the same surgical technique and postoperative guidance conduct by the surgeon. study variables: it is intended to analyse the socio-demographic variables: sex, age, level of education; independent variables: surgical technique, recovery time, difficulties experienced during the postoperative period, possible surgical complications; dependent variables: signs and symptoms postoperatively (presence or absence) and monitoring of care during the postoperative period; level of knowledge about the post-op of orthognathic surgery and anxiety levels (state-trait anxiety inventory-idate).

Eligibility criteria:
inclusion criteria: * patients undergoing orthognathic surgery during the study and with surgical technique: * sagittal maxillary bilateral osteotomy; * maxillary; * vertical osteotomy; * lefort i osteotomy combined with or without mentoplastia and maxillary disjunction. * informed consent * patients in the maxillofacial outpatient clinic located at sao paulo exclusion criteria: * patients undergoing reoperation of orthognathic surgery; * with cleft lip-palate.

Keywords: anxiety orthognathic surgery patient educational as topic patient educational handout pamphlets
intraoperative posterior cruciate ligament (transcruciate) injection after total knee arthroplasty (tka)

Conditions: Arthroplasty, Replacement, Knee

Summary: his study is being done because total knee replacements can leave patients with considerable pain after surgery. therefore, many studies have been done to find the best ways to control knee pain after the surgery. currently, a popular approach is to use many different techniques to control the pain. this includes injecting freezing (local anesthetic) into the spinal column (spinal anesthetic), injecting freezing close to the nerves of the knee and using various kinds of medications (e.g. narcotics and anti-inflammatory medications). studies have shown using this a combination of techniques can reduce pain and allow earlier discharge from the hospital. however, one downside to this approach is it does not usually control the pain in the back of the knee. one new technique has been used to try and overcome this. this technique is called a "posterior cruciate ligament block" or "pcl block". it involves injecting a drug into the back of the knee which will block the nerves in this area. sometimes the investigators refer to this as "freezing". the purpose of our study is to determine whether this "pcl block" will improve pain after the total knee replacement surgery. the investigators will also determine whether this technique will improve movement in the knee and lessen narcotic usage after the surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists' (asa) physical status classification (asa) i and ii patients undergoing unilateral total knee arthroplasty at saskatoon city hospital * patients recruited from the practice of 4 orthopedic surgeons exclusion criteria: * inability to obtain informed consent * simultaneous bilateral total knee arthroplasty or revision cases * preexisting neurological deficits in the distribution of the femoral nerve or known diagnosis of peripheral neuropathy * coagulopathies * infection either systemically or at the needle insertion sites * allergies to local anesthetics or opioids * patients with a history of narcotic dependency or chronic pain * asa iii and iv * body mass index (bmi) \> 40
evaluating illustrated vs. traditional pamphlets for enhancing self-care in radiation therapy patients

Conditions: Radiation Therapy; Head Neck Cancer; Breast Cancer Invasive

Summary: this quasi-experimental study utilized a pre- and post-test design with experimental and control groups to assess the effectiveness of optimized illustrated educational pamphlets in enhancing patient self-care cognition, satisfaction, and reducing anxiety. the experimental group received pamphlets with a combination of images and highlighted text, while the control group received traditional text-based pamphlets. the study targeted patients undergoing radiation therapy (rt) for head and neck or breast cancer for the first time. pre-tests assessed baseline self-care cognition, and post-tests were conducted two weeks after treatment completion. the primary objective was to improve patient awareness and understanding of self-care, aiming to support both mental and physical well-being during rt.

this quasi-experimental, pre- and post-test comparison study was conducted from november 2, 2023, to august 31, 2024, at a medical center in central taiwan, following institutional review board approval (irb no. cs2-23058). a total of 200 first-time rt patients with head and neck or breast cancer were enrolled and randomized into two groups of 100 patients each. the experimental group received optimized illustrated pamphlets covering essential rt information, common side effects, and self-care principles, while the control group received traditional text-based pamphlets.

Eligibility criteria:
inclusion criteria: * participants with clear consciousness. * participants could understand and comprehend mandarin chinese. exclusion criteria: * participants with impaired consciousness or decreased cognitive abilities.
etanercept treatment in patients with moderate to severe plaque psoriasis who lost response to adalimumab

Conditions: Psoriasis

Summary: this study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.


Eligibility criteria:
inclusion criteria: * moderate to severe plaque psoriasis * loss of satisfactory response to adalimumab * currently receiving or recently discontinued treatment with adalimumab exclusion criteria: * active skin conditions that would interfere with evaluations of the effect of investigational product on psoriasis * serious medical conditions

Keywords: plaque psoriasis etanercept adalimumab
perioperative outcome risk assessment with computer learning enhancement

Conditions: Morality; Acute Kidney Injury

Summary: this study will test whether anesthesiology clinicians working in a telemedicine setting can predict patient risk for postoperative complications (death and acute kidney injury) more accurately with access to a machine learning display than without it.

the perioperative outcome risk assessment with computer learning enhancement (periop oracle) study will be a sub-study nested within the ongoing tectonics trial (nct03923699). tectonics is a single-center randomized clinical trial assessing the impact of an anesthesiology control tower (act) on postoperative 30-day mortality, delirium, respiratory failure, and acute kidney injury. as part of the tectonics trial, investigators in the act perform medical record case reviews during the early part of surgery and document how likely they feel each patient is to experience postoperative death and acute kidney injury (aki). in periop oracle, these case reviews will be randomized to be performed with or without access to machine learning (ml) predictions. investigators in the act will conduct all case reviews by viewing the patient's records in alertwatch (alertwatch, ann arbor, mi) and epic (epic, verona, wi). alertwatch is an fda-approved patient monitoring system designed for use in the operating room. the version of alertwatch used in this study has been customized for use in a telemedicine setting. epic is the electronic health record system utilized at barnes-jewish hospital. each case review will be randomized in a 1:1 fashion to be completed with or without ml assistance. if the case review is randomized to ml assistance, the investigator will access a display interface (currently deployed as a web application on a secure server) that shows real-time ml predicted likelihood for postoperative death and postoperative aki. if the case review is not randomized to ml assistance, the investigator will not access this display. after viewing the patient's data, the investigator will predict how likely the patient is to experience postoperative death and postoperative aki and will document this prediction. the area under the receiver operating characteristic curves for predictions made with ml assistance and without ml assistance will be compared.

Eligibility criteria:
inclusion criteria: * surgery in the main operating suite at barnes-jewish hospital * surgery during hours of act operation (weekdays 7:00am-4:00pm) * enrolled in the tectonics randomized clinical trial (nct03923699) exclusion criteria: * none
shock wave therapy versus neuromuscular training in women with patellofemoral pain

Conditions: Patellofemoral Pain Syndrome; Knee Pain Chronic

Summary: the aim of the trial is to compare the efficacy of extracorporeal shock wave therapy (eswt) versus neuromuscular training (tr) in reducing pain in women with patellofemoral pain (pfp). women with pfp will be randomly divided into two therapeutic groups: eswt and tr. the eswt group will undergo extracorporeal shock wave therapy to the iliotibial band and tensor fascia latae. the tr group will be treated with neuromuscular training. the women's gait will be analysed and the strength of hip abductors and internal rotators will be measured. additionally, the women's pain and health status will be assessed with the visual analogue scale and the lysholm scale. outcomes will be registered at baseline, and then at five weeks and at three months post-therapy


Eligibility criteria:
inclusion criteria: knee pain for more than three months greater than three on the visual analogue scale (vas) during at least two out of four typical activities: 1. ascending or descending the stairs, 2. prolonged sitting with flexed knee, 3. running or jumping, 4. squatting or kneeling. exclusion criteria: 1. orthopaedic diagnosis other than pfp. 2. patients with neurological disorders, history of injury or operations within the symptomatic leg, rheumatoid disease, or pregnancy were also excluded from the study.
safety, tolerability, and immunogenicity of an investigational vaccine with recombinant human albumin (rha) in children 12 to 18 months of age (v205c-009)(completed)

Conditions: Measles; Mumps; Rubella; Varicella

Summary: the purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.

the duration of treatment is 6 weeks.

Eligibility criteria:
inclusion criteria: * healthy children 12 to 18 months of age exclusion criteria: * history or prior exposure to measles, mumps, or rubella * history of allergic reactions to any component of the vaccines as evaluated by the study doctor
response to gsk biologicals' tritanrix-hepb/hib-menac vacc (4th dose) at 15-24m & mencevax acwy at 24-30m

Conditions: Whole Cell Pertussis; Haemophilus Influenzae Type b; Hepatitis B; Diphtheria; Tetanus; Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Summary: the purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of dtpw-hbv/hib-menac compared to dtpw-hbv/hib given to healthy subjects at 15 to 24 months of age primed with 3 doses of tritanrix-hepb/hib-menac in study 100480. antibody persistence will be evaluated at 24 to 30 months. immunogenicity, safety and reactogenicity of a dose of mencevax acwy given at 24 to 30 months will also be evaluated when given to subjects not boosted with a mena conjugate and/or menc containing vaccine.

this study will be conducted in two stages. in the dtp booster phase subjects will receive a booster dose of tritanrix-hepb/hib-menac or tritanrix-hepb/hib (active control) at 15 to 24 months in a single-blind manner so that the subjects' parents will not know which vaccine was administered to their child (this booster phase is no longer recruiting). in the mencevax acwy phase at 24-30 months a dose of mencevax acwy will be given to subjects who were not boosted with a mena conjugate and/or menc containing vaccine at 15-24 months in an open manner (this booster phase is not yet recruiting). up to four blood samples will be taken: before and one month after the administration of the dtp booster dose and of mencevax acwy. to comply with the immunisation calender of thailand, at 15-24 months all subjects will receive opv. at 16-25 months 2 doses of japanese encephalitis (je) vaccine or a dose of varicella vaccine will be offered and at 25-31 months a dose of varicella or je vaccine will be offered.

Eligibility criteria:
inclusion criteria: * healthy male or female between and including 15 and 24 months of age * having participated in the primary vaccination study dtpw-hbv=hib-menac-tt-003 (etrack no. 100480) exclusion criteria: * booster vaccination against diphtheria, tetanus, pertussis, hepatitis b, haemophilus influenzae type b (hib) and/or meningococcal serogroups a and/or c disease not foreseen in the protocol, after the date of the study conclusion visit of the primary vaccination study dtpw-hbv=hib-menac-tt-003 (etrack no. 100480). * history of or known exposure to diphtheria, tetanus, pertussis, hepatitis b, hib and/or meningococcal serogroup a or c disease. * any confirmed or suspected immunosuppressive or immunodeficient condition. * a family history of congenital or hereditary immunodeficiency. * major congenital defects or serious chronic illness. * history of any neurologic disorders or seizures including febrile seizures (at least two events) in infancy.

Keywords: prophylaxis diphtheria hib & meningococcal serogroup a & c disease
impact of kegel exercise on post turp outcomes

Conditions: BPH (Benign Prostatic Hyperplasia)

Summary: how kegel exercise will reduce post turp complication and improve patient outcomes

patients will divided in to two group study and control, study group will perform kegel exercise pre and postoperative while control group receive routine care and followed for 6 month

Eligibility criteria:
inclusion criteria: * patient diagnosed with bph and undergoing turp * patient age range from 45-65years old * patient understand verbal and written instructions exclusion criteria: patient confirmed diagnosis with prostate cancer (biopsy-psa) conversion to open prostatectomy patient has cognitive impairment patient has chronic cough /chronic bronchitis or asthma

Keywords: kegel exercise,turp, patient outcomes and bph